ETON (Eton Pharmaceuticals) NonCurrent Deferred Liabilities : $0.00 Mil (As of Sep. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Eton Pharmaceuticals NonCurrent Deferred Liabilities?

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Eton Pharmaceuticals's non-current deferred liabilities for the quarter that ended in Sep. 2024 was $0.00 Mil.

Eton Pharmaceuticals NonCurrent Deferred Liabilities Historical Data

The historical data trend for Eton Pharmaceuticals's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eton Pharmaceuticals NonCurrent Deferred Liabilities Chart

Eton Pharmaceuticals Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

NonCurrent Deferred Liabilities

Get a 7-Day Free Trial

Eton Pharmaceuticals Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
NonCurrent Deferred Liabilities	Get a 7-Day Free Trial															-	-	-	-	-

Eton Pharmaceuticals NonCurrent Deferred Liabilities Related Terms

Thank you for viewing the detailed overview of Eton Pharmaceuticals's NonCurrent Deferred Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Eton Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Eton Pharmaceuticals Inc (NAS:ETON) » Definitions » NonCurrent Deferred Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

21925 West Field Parkway, Suite 235, Deer Park, IL, USA, 60010-7278

Website

https://www.etonpharma.com

Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.

Executives

Opaleye Management Inc.	10 percent owner	ONE BOSTON PLACE, SUITE 2600, BOSTON MA 02108
David Krempa	officer: Chief Business Officer	29125 W FIELD PARKWAY, SUITE 235, DEER PARK IL 60010
Sean Brynjelsen	director, officer: President & CEO	C/O ETON PHARMACEUTICALS, INC., 21925 W FIELD PKWY #235, DEER PARK IL 60010
James R. Gruber	officer: Chief Financial Officer	618 AMES STREET, LIBERTYVILLE IL 60048
William Wilson Troutman	officer: CFO, Treasurer & Secretary	21925 W FIELD PARKWAY, SUITE 235, DEER PARK IL 60010
Imprimis Pharmaceuticals, Inc.	10 percent owner	102 WOODMONT BLVD, SUITE 610, NASHVILLE TN 37215
Jennifer Mckie Adams	director	5410 TENNESSEE AVE, NASHVILLE TN 37209
Charles J Casamento	director	99 BELBROOK WAY, ATHERTON CA 94027
Norbert G Riedel	director	BAXTER INTERNATIONAL INC, ONE BAXTER PKWY DF2-1W, DEERFIELD IL 60015
Mark L Baum	director	C/O IMPRIMIS PHARMACEUTICALS, INC, 12264 EL CAMINO REAL, SUITE 350, SAN DIEGO CA 92130
Paul V Maier	director	3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121